$RVMD

Horn Margaret A sold $990K of RVMD

Horn Margaret A (Chief Operating Officer) sold 4,967 shares of Revolution Medicines, Inc. (RVMD) at an average of $199.24 ($195.01–$199.30, $0.99M total) across 2 trades on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Horn Margaret A
Published Sep 18, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RVMD
Neutral
medium confidence
Mentioned
$RVMD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDNeutralLow
01

Why it matters

The transaction provides fresh data on insider holdings and may influence short‑term sentiment.

02

Market read

Primary insider sale; modest materiality for a micro‑cap biotech, limited trading relevance.

03

What to watch

RVMD's recent clinical trial updates or upcoming data releases could offset sell‑off pressure.

Relevance 4/10Novelty 7/10Timing: post‑market filing on 2026‑09‑18

Background

Form 4 filings disclose insider transactions; a C‑suite sale of $990K is a primary source disclosure.

Company-level read

Ticker impact

$RVMDNeutralMedium confidence
Context

COO Horn Margaret A sold ~ $990K of RVMD shares via a 10b5‑1 plan, reducing her holdings to 149,680 shares.

Expected impact

Potential short‑term pressure on RVMD stock, limited to a few percent if market reacts.

Evidence & confidence

C‑suite insider sale of nearly $1M is material for a micro‑cap biotech; however, pre‑arranged plan reduces informational value.

Market effects

May raise caution among biotech investors monitoring insider activity.

Limited to US biotech sector, no broader regional effect.

Minimal global impact; only relevant to RVMD shareholders.

Counterpoint

The sale could be purely liquidity‑driven under a 10b5‑1 plan, not a negative signal.

Key entities

  • Revolution Medicines, Inc.

    Biotech firm developing therapies for rare diseases.

  • Horn Margaret A

    Chief Operating Officer of Revolution Medicines.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

$RVMDMed

October 2026 EMA/CHMP recommendations

The European Medicines Agency's CHMP recommended six medicines, including Revolution Medicines' Rasonque, for approval. Rasonque targets metastatic pancreatic cancer and was prioritized under EMA's Cancer Medicines Pathfinder project.

$RVMDHigh

Guggenheim reiterates Buy on Revolution stock after EU regulatory opinion

Guggenheim maintained a Buy rating and $275 price target on Revolution Medicines (NASDAQ:RVMD) after the European Medicines Agency recommended approval of its drug Rasonque. The stock has risen 281% in the past year, though some analysts suggest it may be overvalued. Multiple firms have recently initiated coverage with positive ratings and price targets ranging from $226 to $318.

$LLYHigh

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

$RVMDHigh

William Blair initiates Revolution stock with outperform on RAS franchise

William Blair initiated coverage on Revolution Medicines (RVMD) with an Outperform rating and a $226 price target. The stock has gained 281% over the past year. The FDA approved Rasonque (daraxonrasib) for pancreatic cancer, with trials showing improved survival rates. Analysts cite strong early launch trends and commercial potential, though some note overvaluation. Multiple firms raised price targets following the approval.

$RVMDMed

Revolution Medicines receives EU committee backing for pancreatic cancer drug

Revolution Medicines (RVMD) announced the EMA's Committee for Medicinal Products for Human Use issued a positive opinion for RASONQUE as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma. The recommendation is based on Phase 3 trial results showing RASONQUE improved overall survival (13.2 months vs. 6.7 months with chemotherapy) and progression-free survival (7.2 months vs. 3.6 months). The EMA's expedited review process was used.